Robert S. Svatek

11.6k total citations · 1 hit paper
211 papers, 6.2k citations indexed

About

Robert S. Svatek is a scholar working on Surgery, Urology and Oncology. According to data from OpenAlex, Robert S. Svatek has authored 211 papers receiving a total of 6.2k indexed citations (citations by other indexed papers that have themselves been cited), including 165 papers in Surgery, 50 papers in Urology and 45 papers in Oncology. Recurrent topics in Robert S. Svatek's work include Bladder and Urothelial Cancer Treatments (153 papers), Urinary and Genital Oncology Studies (103 papers) and Urological Disorders and Treatments (44 papers). Robert S. Svatek is often cited by papers focused on Bladder and Urothelial Cancer Treatments (153 papers), Urinary and Genital Oncology Studies (103 papers) and Urological Disorders and Treatments (44 papers). Robert S. Svatek collaborates with scholars based in United States, Canada and Germany. Robert S. Svatek's co-authors include Yair Lotan, Shahrokh F. Shariat, Colin P. Dinney, Ashish M. Kamat, Arthur I. Sagalowsky, Pierre I. Karakiewicz, Dipen J. Parekh, Jamie Messer, Richard Lee and Sten Holmäng and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Oncology.

In The Last Decade

Robert S. Svatek

204 papers receiving 6.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Economics of Bladder Cancer: Costs and Considerations of Caring for This Disease

2014 393 citations Robert S. Svatek, Yair Lotan et al. European Urology profile →

Peers

Countries citing papers authored by Robert S. Svatek

Since Specialization

Citations

This map shows the geographic impact of Robert S. Svatek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert S. Svatek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert S. Svatek more than expected).

Fields of papers citing papers by Robert S. Svatek

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert S. Svatek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert S. Svatek. The network helps show where Robert S. Svatek may publish in the future.

Co-authorship network of co-authors of Robert S. Svatek

This figure shows the co-authorship network connecting the top 25 collaborators of Robert S. Svatek. A scholar is included among the top collaborators of Robert S. Svatek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert S. Svatek. Robert S. Svatek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Molecular Subtyping for Predicting Pathological Upstaging and Survival Outcomes in Clinically Organ-confined Bladder Cancer Patients Undergoing Radical Cystectomy 2025 ·European Urology Open Science ·Joep J. de Jong, (unknown), Siamak Daneshmand, Robert S. Svatek, Vikram M. Narayan, Elai Davicioni, Shreyas Joshi, (unknown), Roger Li, Brant A. Inman, Paras Shah, (unknown), Jonathan L. Wright, Ewan A. Gibb, Yair Lotan	1
2	Two-year resource utilization of open vs. robot-assisted radical cystectomy: Results from optum's de-identified clinformatics® data mart database 2025 ·Urologic Oncology Seminars and Original Investigations ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Trudy Millard Krause, Michael A. Liss, Dharam Kaushik, Robert S. Svatek, Ahmed M. Mansour	1
3	A luminal non‐coding RNA‐based genomic classifier confirms favourable outcomes in patients with clinically organ‐confined bladder cancer treated with radical cystectomy 2024 ·British Journal of Urology ·Joep J. de Jong, (unknown), Siamak Daneshmand, Robert S. Svatek, Vikram M. Narayan, Ewan A. Gibb, Elai Davicioni, Shreyas Joshi, (unknown), Roger Li, Brant A. Inman, Paras Shah, (unknown), Jonathan L. Wright, Yair Lotan	1
4	The Laws of Attraction: Chemokines as Critical Mediators in Cancer Progression and Immunotherapy Response in Bladder Cancer 2024 ·Cancers ·(unknown), (unknown), (unknown), Manjeet K. Rao, Nu Zhang, Gang Huang, Robert S. Svatek, Neelam Mukherjee	1
5	Commentary on Novitas LCD 2023 ·Bladder Cancer ·Yair Lotan, Daniel A. Barocas, Sam S. Chang, Siamak Daneshmand, Badrinath R. Konety, Joshua J. Meeks, Sima P. Porten, Jay D. Raman, Charles J. Rosser, Kristen R. Scarpato, Wade J. Sexton, John P. Sfakianos, Neal D. Shore, Robert S. Svatek	1
6	Impact of rural residence on the presentation, management and survival of patients with non-metastatic muscle-invasive bladder carcinoma 2023 ·Investigative and Clinical Urology ·(unknown), (unknown), Hanzhang Wang, Dharam Kaushik, Michael A. Liss, Robert S. Svatek, John L. Gore, Ahmed M. Mansour	1
7	Revisiting current National Comprehensive Cancer Network (NCCN) high-risk prostate cancer stratification: a National Cancer Database analysis 2023 ·Prostate Cancer and Prostatic Diseases ·Harshit Garg, (unknown), (unknown), Hanzhang Wang, Shenghui Wu, Michael A. Liss, Dharam Kaushik, Robert S. Svatek, Ahmed M. Mansour	6
8	Patency outcomes of primary inferior vena cava repair in radical nephrectomy and tumor thrombectomy 2023 ·Journal of Vascular Surgery Venous and Lymphatic Disorders ·Harshit Garg, Philip Whalen, (unknown), Robert Cooper, (unknown), (unknown), (unknown), Lalithapriya Jayakumar, Michael A. Liss, Robert S. Svatek, Ronald Rodríguez, Dharam Kaushik, Deepak Pruthi	2
9	Histological variants of non–muscle invasive bladder cancer: Survival outcomes of radical cystectomy vs. bladder preservation therapy 2022 ·Urologic Oncology Seminars and Original Investigations ·(unknown), (unknown), Hanzhang Wang, Shenghui Wu, Michael A. Liss, Dharam Kaushik, (unknown), Robert S. Svatek, Ahmed M. Mansour	9
10	γδ T Cells Support Antigen-Specific αβ T cell–Mediated Antitumor Responses during BCG Treatment for Bladder Cancer 2021 ·Cancer Immunology Research ·Niannian Ji, Neelam Mukherjee, (unknown), (unknown), Joshua J. Meeks, David J. McConkey, Jonathan Gelfond, Tyler J. Curiel, Robert S. Svatek	15
11	Bladder cancer cell‐intrinsic PD‐L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy 2021 ·Cancer Medicine ·Deyi Zhang, (unknown), (unknown), (unknown), Harshita B. Gupta, Álvaro Padrón, Anand Kornepati, (unknown), Xiujie Sun, Yilun Deng, Bogang Wu, Ratna K. Vadlamudi, Rong Li, Robert S. Svatek, Tyler J. Curiel	34
12	Y-Box Binding Protein 1 Regulates Angiogenesis in Bladder Cancer via miR-29b-3p-VEGFA Pathway 2021 ·Journal of Oncology ·(unknown), Qian Niu, Yuwen Gong, (unknown), Su Zhang, Yuhan Wang, (unknown), Hanzhang Wang, Robert S. Svatek, Ronald Rodríguez, (unknown), Zhiping Wang	7
13	Pathological downstaging following radical cystectomy for muscle-invasive bladder cancer: Survival outcomes in the setting of neoadjuvant chemotherapy versus transurethral resection only 2020 ·Urologic Oncology Seminars and Original Investigations ·(unknown), Hanzhang Wang, (unknown), Dharam Kaushik, Michael A. Liss, Robert S. Svatek, Shenghui Wu, Wasim H. Chowdhury, Chethan Ramamurthy, Ahmed M. Mansour	4
14	Adaptive Immune Resistance to Intravesical BCG in Non–Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials 2019 ·Clinical Cancer Research ·Max Kates, Andrés Matoso, Woonyoung Choi, Alexander S. Baras, Marcus J. Daniels, Kara A. Lombardo, Aaron Brant, (unknown), David J. McConkey, Ashish M. Kamat, Robert S. Svatek, Sima P. Porten, Joshua J. Meeks, Seth P. Lerner, Colin P. Dinney, Peter C. Black, James M. McKiernan, Chris Anderson, Charles G. Drake, Trinity J. Bivalacqua	109
15	Rapamycin Prevents Surgery-Induced Immune Dysfunction in Patients with Bladder Cancer 2018 ·Cancer Immunology Research ·Robert S. Svatek, Niannian Ji, (unknown), Neelam Mukherjee, (unknown), Vincent Hurez, Marlo Nicolas, Joel Michalek, Martin A. Javors, Karen Wheeler, Z. Dave Sharp, Carolina B. Livi, (unknown), (unknown), Tyler J. Curiel	20
16	Age effects of distinct immune checkpoint blockade treatments in a mouse melanoma model 2018 ·Experimental Gerontology ·Álvaro Padrón, Vincent Hurez, Harshita B. Gupta, Curtis A. Clark, (unknown), Bin Yuan, Robert S. Svatek, Mary Jo Turk, Justin Drerup, Rong Li, Tyler J. Curiel	33
17	Immune-Stimulatory Effects of Rapamycin Are Mediated by Stimulation of Antitumor γδ T Cells 2016 ·Cancer Research ·Vinh Dao, Yang Liu, Srilakshmi Pandeswara, Robert S. Svatek, Jonathan Gelfond, Aijie Liu, Vincent Hurez, Tyler J. Curiel	32
18	Sequential Intravesical Mitomycin plus Bacillus Calmette–Guérin for Non–Muscle-Invasive Urothelial Bladder Carcinoma: Translational and Phase I Clinical Trial 2014 ·Clinical Cancer Research ·Robert S. Svatek, (unknown), (unknown), Mithilesh Kumar Jha, Timothy Y. Tseng, (unknown), Vincent Hurez, Javier Hernández, Tyler J. Curiel	28
19	Definition, Incidence, Risk Factors, and Prevention of Paralytic Ileus Following Radical Cystectomy: A Systematic Review 2012 ·European Urology ·Jorge A. Ramirez, Andrew G. McIntosh, (unknown), Valerie A. Lawrence, Dipen J. Parekh, Robert S. Svatek	74
20	Urine-based biomarkers for the early detection and surveillance of non-muscle invasive bladder cancer. 2008 ·PubMed ·Michael Herman, Robert S. Svatek, Yair Lotan, Pierre Karakiewizc, Shahrokh F. Shariat	37

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact